Literature DB >> 21932134

Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions.

Toshitatsu Ogino1, Hideya Onishi, Hiroyuki Suzuki, Takashi Morisaki, Masao Tanaka, Mitsuo Katano.   

Abstract

Dendritic cells (DCs) generated from monocytes under 20% O2 are now used as therapeutic tools for cancer patients. However, the O2 concentration is between 3 and 0.5% in most tissues. We evaluated these complicated functions of DCs under oxygen tensions mimicking in vivo situations. Immature DCs (imDCs) were generated from monocytes using IL-4 and GM-CSF under normoxia (20% O2; N-imDCs) or hypoxia (1% O2; H-imDCs). Mature DCs (mDCs) were induced with LPS. DCs were further exposed to normoxia (N/N-DCs) or hypoxia (N/H-DCs and H/H-DCs) conditions. Using a 2-D culture system, H-DCs were smaller in size than N-DCs, and H/H-DCs exhibited higher allo-T cell stimulation ability than N/N-DCs and N/H-DCs. On the other hand, motility and phagocytic ability of H/H-DCs were significantly lower than those of N/H-DCs and N/N-DCs. In a 3-D culture system, however, maturation of H/H-imDCs and N/H-imDCs was suppressed compared with N/N-imDCs as a result of their decreased motility and phagocytosis. Interestingly, silencing of HIF-1α by RNA interference decreased CD83 expression without affecting any antigen presentation abilities except for the ability to stimulate the allo-T cell population. Our data could help our understanding of DCs, especially therapeutic DCs, in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932134     DOI: 10.1007/s00262-011-1112-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Authors:  Shujing Shi; Rui Wang; Yitian Chen; Haizhu Song; Longbang Chen; Guichun Huang
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

Review 2.  Hypoxia-Inducible Factor (HIF) as a Pharmacological Target for Prevention and Treatment of Infectious Diseases.

Authors:  Tamara Bhandari; Victor Nizet
Journal:  Infect Dis Ther       Date:  2014-06-24

Review 3.  Dendritic Cells under Hypoxia: How Oxygen Shortage Affects the Linkage between Innate and Adaptive Immunity.

Authors:  Sandra Winning; Joachim Fandrey
Journal:  J Immunol Res       Date:  2016-02-04       Impact factor: 4.818

4.  The hypoxia-responsive lncRNA NDRG-OT1 promotes NDRG1 degradation via ubiquitin-mediated proteolysis in breast cancer cells.

Authors:  Hsin-Chen Lin; Ching-Ching Yeh; Lo-Yun Chao; Mong-Hsun Tsai; Hung-Hsin Chen; Eric Y Chuang; Liang-Chuan Lai
Journal:  Oncotarget       Date:  2017-12-28

5.  Trichostatin a Protects Dendritic Cells Against Oxygen-Glucose Deprivation via the SRSF3/PKM2/Glycolytic Pathway.

Authors:  Hongyun Jiang; Siwei Zhang; Tongtong Song; Xin Guan; Ruojin Zhang; Xia Chen
Journal:  Front Pharmacol       Date:  2018-06-11       Impact factor: 5.810

Review 6.  Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.

Authors:  S K Daniel; K M Sullivan; K P Labadie; V G Pillarisetty
Journal:  Clin Transl Med       Date:  2019-04-01

Review 7.  Dendritic Cells as Sensors, Mediators, and Regulators of Ischemic Injury.

Authors:  Helong Dai; Angus W Thomson; Natasha M Rogers
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

8.  Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.

Authors:  Dongjie Chen; Hui Huang; Longjun Zang; Wenzhe Gao; Hongwei Zhu; Xiao Yu
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.